Concise Review: Process Development Considerations for Cell Therapy

The development of robust and well‐characterized methods of production of cell therapies has become increasingly important as therapies advance through clinical trials toward approval. A successful cell therapy will be a consistent, safe, and effective cell product, regardless of the cell type or application. Process development strategies can be developed to gain efficiency while maintaining or improving safety and quality profiles. This review presents an introduction to the process development challenges of cell therapies and describes some of the tools available to address production issues. This article will provide a summary of what should be considered to efficiently advance a cellular therapy from the research stage through clinical trials and finally toward commercialization. The identification of the basic questions that affect process development is summarized in the target product profile, and considerations for process optimization are discussed. The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful.

[1]  C. Mason,et al.  Cell therapy industry: billion dollar global business with unlimited potential. , 2011, Regenerative medicine.

[2]  Chris Mason,et al.  Peak serum: implications of serum supply for cell therapy manufacturing. , 2012, Regenerative medicine.

[3]  H. Brandwein,et al.  Concise Review: Guidance in Developing Commercializable Autologous/Patient‐Specific Cell Therapy Manufacturing , 2013, Stem cells translational medicine.

[4]  Jon A. Rowley,et al.  Meeting Lot-Size Challenges of Manufacturing Adherent Cells for Therapy , 2012 .

[5]  S. Reuveny,et al.  Microcarrier suspension cultures for high-density expansion and differentiation of human pluripotent stem cells to neural progenitor cells. , 2013, Tissue engineering. Part C, Methods.

[6]  Hemanthram Varadaraju,et al.  Downstream Technology Landscape for Large-Scale Therapeutic Cell Processing , 2013 .

[7]  M. Choolani,et al.  Microcarrier Culture for Efficient Expansion and Osteogenic Differentiation of Human Fetal Mesenchymal Stem Cells , 2013, BioResearch open access.

[8]  Anurag S Rathore,et al.  Roadmap for implementation of quality by design (QbD) for biotechnology products. , 2009, Trends in biotechnology.

[9]  Yuanxing Zhang Approaches to optimizing animal cell culture process: substrate metabolism regulation and protein expression improvement. , 2009, Advances in biochemical engineering/biotechnology.

[10]  G. Chun,et al.  Development of high density mammalian cell culture system for the production of tissue-type plasminogen activator , 2000 .

[11]  S. Reuveny,et al.  Agitation can induce differentiation of human pluripotent stem cells in microcarrier cultures. , 2011, Tissue engineering. Part C, Methods.

[12]  Ye Zhang,et al.  Very High Density of CHO Cells in Perfusion by ATF or TFF in WAVE Bioreactor™. Part I. Effect of the Cell Density on the Process , 2013, Biotechnology progress.

[13]  A S Rathore,et al.  Process analytical technology (PAT) for biopharmaceutical products , 2010, Analytical and bioanalytical chemistry.

[14]  Carl-Fredrik Mandenius,et al.  Bioprocess optimization using design‐of‐experiments methodology , 2008, Biotechnology progress.

[15]  Alvin W. Nienow,et al.  A potentially scalable method for the harvesting of hMSCs from microcarriers , 2014 .

[16]  D. Gilmore,et al.  Statistical experimental design for bioprocess modeling and optimization analysis , 2006, Applied biochemistry and biotechnology.

[17]  Jeremy J Mao,et al.  Shear stress induces osteogenic differentiation of human mesenchymal stem cells. , 2010, Regenerative medicine.

[18]  S. Shire Current trends in monoclonal antibody development and manufacturing , 2010 .

[19]  Bryan S. Riley,et al.  Quality by Design and Process Analytical Technology for Sterile Products—Where Are We Now? , 2011, AAPS PharmSciTech.